Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease.
Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, Jerome KR, McCune JS, Storer B, Martin P, Appelbaum F, Abonour R, Westervelt P, Anasetti C. Carpenter PA, et al. Among authors: mccune js. Biol Blood Marrow Transplant. 2005 Jun;11(6):465-71. doi: 10.1016/j.bbmt.2005.03.002. Biol Blood Marrow Transplant. 2005. PMID: 15931635 Free article. Clinical Trial.
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, Furlong T, Anasetti C, Appelbaum FR, Lloid ME, Deeg HJ, Kiem HP, Martin PJ, Schubert MM, Witherspoon RP, Forman SJ, Blume KG, Storb R. Nash RA, et al. Among authors: mccune js. Biol Blood Marrow Transplant. 2005 Jul;11(7):495-505. doi: 10.1016/j.bbmt.2005.03.006. Biol Blood Marrow Transplant. 2005. PMID: 15983549 Free article. Clinical Trial.
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D, Heimfeld S, Flowers ME, Anasetti C, Doney KC, Hansen JA, Kiem HP, Nash RA, O'Donnell PV, Radich JP, Sandmaier BM, Scott BL, Sorror ML, Warren EH, Witherspoon RP, Woolfrey A, Appelbaum FR, Storb R. Deeg HJ, et al. Among authors: mccune js. Biol Blood Marrow Transplant. 2006 May;12(5):573-84. doi: 10.1016/j.bbmt.2005.12.036. Biol Blood Marrow Transplant. 2006. PMID: 16635793 Free article. Clinical Trial.
Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation.
Upton A, McCune JS, Kirby KA, Leisenring W, McDonald G, Batchelder A, Marr KA. Upton A, et al. Among authors: mccune js. Biol Blood Marrow Transplant. 2007 Jul;13(7):760-4. doi: 10.1016/j.bbmt.2007.03.005. Epub 2007 Apr 30. Biol Blood Marrow Transplant. 2007. PMID: 17580253 Free PMC article. Clinical Trial.
Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy.
McCune JS, Batchelder A, Guthrie KA, Witherspoon R, Appelbaum FR, Phillips B, Vicini P, Salinger DH, McDonald GB. McCune JS, et al. Clin Pharmacol Ther. 2009 Jun;85(6):615-22. doi: 10.1038/clpt.2009.27. Epub 2009 Mar 18. Clin Pharmacol Ther. 2009. PMID: 19295506 Free PMC article. Clinical Trial.
144 results